---
document_datetime: 2025-12-29 11:28:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zejula.html
document_name: zejula.html
version: success
processing_time: 0.1296096
conversion_datetime: 2025-12-30 02:49:21.33423
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zejula

[RSS](/en/individual-human-medicine.xml/66776)

##### Authorised

This medicine is authorised for use in the European Union

niraparib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zejula](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77969)
- [More information on Zejula](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zejula is a cancer medicine used in women with advanced ovarian cancer, which includes cancer of the ovaries, fallopian tubes (that connect the ovaries to the uterus) or the peritoneum (the lining around the abdomen). It can be used on its own for maintenance (continuing) treatment:

- In women newly diagnosed with advanced cancer in whom the cancer has shrunk or disappeared with a platinum-based medicines;
- in women whose cancer had relapsed (come back) after responding to previous treatment and in whom the cancer has shrunk or disappeared with a platinum-based medicine

Ovarian cancer is rare and Zejula was designated an 'orphan medicine' (a medicine used in rare diseases) on 4 August 2010.

Zejula contains the active substance niraparib.

Expand section

Collapse section

## How is Zejula used?

Zejula is available as capsules (100 mg) to be taken by mouth. The dose is 2 or 3 capsules once a day, depending on the patient's weight, platelet count and whether or not the cancer has come back after previous treatment. Treatment should continue for as long as the patient benefits from it. The doctor may interrupt treatment or reduce the dose if the patient has certain side effects.

The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the use of cancer medicines.

For more information about using Zejula, see the package leaflet or contact your doctor or pharmacist.

## How does Zejula work?

The active substance in Zejula, niraparib, blocks the action of enzymes called PARP-1 and PARP-2, which help to repair damaged DNA in cells when the cells divide to make new cells. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and, as a result, the cancer cells die.

## What benefits of Zejula have been shown in studies?

Zejula increased the time women lived without their disease getting worse in two main studies involving over 1,000 women with ovarian cancer, including fallopian tube or peritoneal cancers.

One study involved women with high-grade epithelial ovarian cancer that had come back after previous treatment with two or more platinum-based therapies. The women had a lasting response (the cancer had not progressed for at least 6 months) before the last platinum-based therapy. After treatment with Zejula, women lived on average 11.3 months without their disease getting worse compared with 4.7 months in women receiving placebo (a dummy treatment).

Another study involved women with advanced high-grade epithelial ovarian cancer that had only been treated with a platinum-based medicine and in whom the cancer had shrunk or disappeared. Women who then continued treatment with Zejula lived 13.8 months without their disease getting worse compared with 8.2 months in women receiving placebo (a dummy treatment).

## What are the risks associated with Zejula?

The most common side effects with Zejula (which may affect more than 1 in 10 people) are nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anaemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhoea, dyspnoea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells. Serious side effects include thrombocytopenia and anaemia. For the full list of side effects of Zejula, see the package leaflet.

Zejula must not be used in women who are breastfeeding. For the full list of restrictions, see the package leaflet.

## Why is Zejula authorised in the EU?

Although treatments for advanced ovarian cancer are available, the disease inevitably comes back. Zejula has been shown to prolong the time before the disease gets worse again in patients who have responded to platinum-based therapies. This may allow treatment for ovarian cancer to be delayed. Regarding safety, side effects are generally manageable with dose reductions.

The European Medicines Agency therefore decided that Zejula's benefits are greater than its risks and recommended that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zejula?

The company that markets Zejula will submit the final analyses of the study on the effectiveness of Zejula in advanced epithelial (FIGO Stages III and IV) high-grade ovarian cancer.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zejula have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zejula are continuously monitored. Side effects reported with Zejula are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zejula

Zejula received a marketing authorisation valid throughout the EU on 16 November 2017.

Zejula : EPAR - Medicine overview

Reference Number: EMA/505047/2020

English (EN) (115.64 KB - PDF)

**First published:** 27/11/2017

**Last updated:** 06/11/2020

[View](/en/documents/overview/zejula-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-402)

български (BG) (169.55 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/bg/documents/overview/zejula-epar-medicine-overview_bg.pdf)

español (ES) (142.37 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/es/documents/overview/zejula-epar-medicine-overview_es.pdf)

čeština (CS) (167.32 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/cs/documents/overview/zejula-epar-medicine-overview_cs.pdf)

dansk (DA) (143.01 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/da/documents/overview/zejula-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.93 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/de/documents/overview/zejula-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.2 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/et/documents/overview/zejula-epar-medicine-overview_et.pdf)

ελληνικά (EL) (169.17 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/el/documents/overview/zejula-epar-medicine-overview_el.pdf)

français (FR) (143.45 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/fr/documents/overview/zejula-epar-medicine-overview_fr.pdf)

hrvatski (HR) (163.34 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/hr/documents/overview/zejula-epar-medicine-overview_hr.pdf)

italiano (IT) (141.56 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/it/documents/overview/zejula-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (173.29 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/lv/documents/overview/zejula-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.75 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/lt/documents/overview/zejula-epar-medicine-overview_lt.pdf)

magyar (HU) (164.78 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/hu/documents/overview/zejula-epar-medicine-overview_hu.pdf)

Malti (MT) (166.64 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/mt/documents/overview/zejula-epar-medicine-overview_mt.pdf)

Nederlands (NL) (142.88 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/nl/documents/overview/zejula-epar-medicine-overview_nl.pdf)

polski (PL) (167.62 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/pl/documents/overview/zejula-epar-medicine-overview_pl.pdf)

português (PT) (142.21 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/pt/documents/overview/zejula-epar-medicine-overview_pt.pdf)

română (RO) (162.51 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/ro/documents/overview/zejula-epar-medicine-overview_ro.pdf)

slovenčina (SK) (164.93 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/sk/documents/overview/zejula-epar-medicine-overview_sk.pdf)

slovenščina (SL) (161.98 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/sl/documents/overview/zejula-epar-medicine-overview_sl.pdf)

Suomi (FI) (139.61 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/fi/documents/overview/zejula-epar-medicine-overview_fi.pdf)

svenska (SV) (140.63 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

06/11/2020

[View](/sv/documents/overview/zejula-epar-medicine-overview_sv.pdf)

Zejula : EPAR - Risk management plan

English (EN) (1.35 MB - PDF)

**First published:** 10/06/2020

**Last updated:** 07/05/2025

[View](/en/documents/rmp/zejula-epar-risk-management-plan_en.pdf)

## Product information

Zejula : EPAR - Product Information

English (EN) (918.93 KB - PDF)

**First published:** 27/11/2017

**Last updated:** 26/11/2025

[View](/en/documents/product-information/zejula-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-757)

български (BG) (1.02 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/bg/documents/product-information/zejula-epar-product-information_bg.pdf)

español (ES) (995.53 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/es/documents/product-information/zejula-epar-product-information_es.pdf)

čeština (CS) (995.65 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/cs/documents/product-information/zejula-epar-product-information_cs.pdf)

dansk (DA) (931.95 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/da/documents/product-information/zejula-epar-product-information_da.pdf)

Deutsch (DE) (1.12 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/de/documents/product-information/zejula-epar-product-information_de.pdf)

eesti keel (ET) (866.04 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/et/documents/product-information/zejula-epar-product-information_et.pdf)

ελληνικά (EL) (1010.47 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/el/documents/product-information/zejula-epar-product-information_el.pdf)

français (FR) (950.53 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/fr/documents/product-information/zejula-epar-product-information_fr.pdf)

hrvatski (HR) (884.38 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/hr/documents/product-information/zejula-epar-product-information_hr.pdf)

íslenska (IS) (1.08 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/is/documents/product-information/zejula-epar-product-information_is.pdf)

italiano (IT) (1.02 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/it/documents/product-information/zejula-epar-product-information_it.pdf)

latviešu valoda (LV) (1.01 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/lv/documents/product-information/zejula-epar-product-information_lv.pdf)

lietuvių kalba (LT) (971.74 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/lt/documents/product-information/zejula-epar-product-information_lt.pdf)

magyar (HU) (1.11 MB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/hu/documents/product-information/zejula-epar-product-information_hu.pdf)

Malti (MT) (998.34 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/mt/documents/product-information/zejula-epar-product-information_mt.pdf)

Nederlands (NL) (985.66 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/nl/documents/product-information/zejula-epar-product-information_nl.pdf)

norsk (NO) (1021.28 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/no/documents/product-information/zejula-epar-product-information_no.pdf)

polski (PL) (960.24 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/pl/documents/product-information/zejula-epar-product-information_pl.pdf)

português (PT) (901.98 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/pt/documents/product-information/zejula-epar-product-information_pt.pdf)

română (RO) (1018.69 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/ro/documents/product-information/zejula-epar-product-information_ro.pdf)

slovenčina (SK) (938.86 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/sk/documents/product-information/zejula-epar-product-information_sk.pdf)

slovenščina (SL) (1012.37 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/sl/documents/product-information/zejula-epar-product-information_sl.pdf)

Suomi (FI) (997.62 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/fi/documents/product-information/zejula-epar-product-information_fi.pdf)

svenska (SV) (959.24 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

26/11/2025

[View](/sv/documents/product-information/zejula-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0000303299 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zejula : EPAR - All Authorised presentations

English (EN) (66.04 KB - PDF)

**First published:** 27/11/2017

**Last updated:** 02/02/2024

[View](/en/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-453)

български (BG) (61.94 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/bg/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_bg.pdf)

español (ES) (81.61 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/es/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.19 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/cs/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.65 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/da/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.49 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/de/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.94 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/et/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.42 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/el/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_el.pdf)

français (FR) (63.72 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/fr/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (121.26 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/hr/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.78 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/is/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.72 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/it/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (104.85 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/lv/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.15 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/lt/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.82 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/hu/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.03 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/mt/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.2 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/nl/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66.44 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/no/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.03 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/pl/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_pl.pdf)

português (PT) (44.7 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/pt/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_pt.pdf)

română (RO) (72.27 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/ro/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.8 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/sk/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (85.26 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/sl/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (85.17 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/fi/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (61.98 KB - PDF)

**First published:**

27/11/2017

**Last updated:**

02/02/2024

[View](/sv/documents/all-authorised-presentations/zejula-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zejula Active substance niraparib (tosilate monohydrate) International non-proprietary name (INN) or common name niraparib Therapeutic area (MeSH)

- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Ovarian Neoplasms

Anatomical therapeutic chemical (ATC) code L01XK02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Zejula is indicated:

- as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/004249

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 14/09/2017 Marketing authorisation issued 16/11/2017 Revision 28

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zejula : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (162.6 KB - PDF)

**First published:** 26/11/2025

[View](/en/documents/procedural-steps-after/zejula-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zejula : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (277.21 KB - PDF)

**First published:** 01/02/2018

**Last updated:** 26/11/2025

[View](/en/documents/procedural-steps-after/zejula-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zejula-H-C-004249-X-0029 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/294945/2022

English (EN) (1.18 MB - PDF)

**First published:** 13/06/2022

[View](/en/documents/variation-report/zejula-h-c-004249-x-0029-epar-assessment-report-variation_en.pdf)

Zejula-H-C-PSUSA-00010655-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/408579/2021

English (EN) (122.47 KB - PDF)

**First published:** 21/07/2021

[View](/en/documents/scientific-conclusion/zejula-h-c-psusa-00010655-202009-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Zejula-H-C-003943-II-0019 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/531223/2020

English (EN) (9.37 MB - PDF)

**First published:** 06/11/2020

[View](/en/documents/variation-report/zejula-h-c-003943-ii-0019-epar-assessment-report-variation_en.pdf)

Zejula : Orphan maintenance assessment report (post-authorisation) (II-019)

Adopted

Reference Number: EMA/OD/0000031233

English (EN) (431.34 KB - PDF)

**First published:** 06/11/2020

[View](/en/documents/orphan-maintenance-report-post/zejula-orphan-maintenance-assessment-report-post-authorisation-ii-019_en.pdf)

CHMP post-authorisation summary of positive opinion for Zejula (II-19)

Adopted

Reference Number: EMA/CHMP/491345/2020

English (EN) (137.15 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zejula-ii-19_en.pdf)

Zejula-H-C-PSUSA-00010655-201909 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/217985/2020

English (EN) (144.47 KB - PDF)

**First published:** 28/07/2020

[View](/en/documents/scientific-conclusion/zejula-h-c-psusa-00010655-201909-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Zejula-H-C-PSUSA-00010655-201809 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/357939/2019

English (EN) (61.63 KB - PDF)

**First published:** 26/06/2019

[View](/en/documents/scientific-conclusion/zejula-h-c-psusa-00010655-201809-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Zejula : EPAR - Public assessment report

Adopted

Reference Number: EMA/648982/2017

English (EN) (4.53 MB - PDF)

**First published:** 27/11/2017

**Last updated:** 27/11/2017

[View](/en/documents/assessment-report/zejula-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zejula

Adopted

Reference Number: EMA/CHMP/574018/2017

English (EN) (68.34 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zejula_en.pdf)

#### News on Zejula

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Zejula : EPAR - Product information - tracked changes

English (EN) (1.42 MB - DOCX)

**First published:** 15/07/2025

[View](/en/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-922)

български (BG) (1.23 MB - DOCX)

**First published:**

15/07/2025

[View](/bg/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.22 MB - DOCX)

**First published:**

15/07/2025

[View](/es/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1.13 MB - DOCX)

**First published:**

15/07/2025

[View](/cs/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (1.32 MB - DOCX)

**First published:**

15/07/2025

[View](/da/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (2.04 MB - DOCX)

**First published:**

15/07/2025

[View](/de/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.07 MB - DOCX)

**First published:**

15/07/2025

[View](/et/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (1.16 MB - DOCX)

**First published:**

15/07/2025

[View](/el/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_el.docx)

français (FR) (1.09 MB - DOCX)

**First published:**

15/07/2025

[View](/fr/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (512.92 KB - DOCX)

**First published:**

15/07/2025

[View](/hr/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (857.58 KB - DOCX)

**First published:**

15/07/2025

[View](/is/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_is.docx)

italiano (IT) (830.76 KB - DOCX)

**First published:**

15/07/2025

[View](/it/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (668.33 KB - DOCX)

**First published:**

15/07/2025

[View](/lv/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (1.32 MB - DOCX)

**First published:**

15/07/2025

[View](/lt/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (1.88 MB - DOC)

**First published:**

15/07/2025

[View](/hu/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (411.3 KB - DOCX)

**First published:**

15/07/2025

[View](/mt/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (1.43 MB - DOCX)

**First published:**

15/07/2025

[View](/nl/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.58 MB - DOCX)

**First published:**

15/07/2025

[View](/no/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_no.docx)

polski (PL) (656 KB - DOCX)

**First published:**

15/07/2025

[View](/pl/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_pl.docx)

português (PT) (793.53 KB - DOCX)

**First published:**

15/07/2025

[View](/pt/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.32 MB - DOCX)

**First published:**

15/07/2025

[View](/ro/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.53 MB - DOC)

**First published:**

15/07/2025

[View](/sk/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (1.34 MB - DOCX)

**First published:**

15/07/2025

[View](/sl/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (712.39 KB - DOCX)

**First published:**

15/07/2025

[View](/fi/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (486.24 KB - DOCX)

**First published:**

15/07/2025

[View](/sv/documents/product-information-tracked-changes/zejula-epar-product-information-tracked-changes_sv.docx)

#### More information on Zejula

- [EU/3/10/760 - orphan designation for treatment of ovarian cancer](/en/medicines/human/orphan-designations/eu-3-10-760)
- [EMEA-002268-PIP03-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002268-pip03-18)
- [EMEA-002268-PIP02-18-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002268-pip02-18-m02)
- [Post-authorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with ZEJULA® (niraparib) (213705 - Zejula PASS 3000-04-001) - post-authorisation study](https://catalogues.ema.europa.eu/study/44185)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/11/2025

## Share this page

[Back to top](#main-content)